First NMOSD therapy gains FDA approval

Eculizumab (Soliris), a first-in-class complement inhibitor, is now approved for AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) following an expedited 6-month priority review.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553